Pfizer Inc. and Astellas Pharma Inc. have announced positive topline results from the Phase 3 EV-303 clinical trial (also ...

In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...

Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in ...

After an unusual first quarter in which seven of the biopharma industry’s | Several U.S. pharma companies that had posted ...

We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Pfizer Inc. (NYSE:PFE) is one of the ...

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer ...

With the end of the pandemic, sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, have declined from their peak. However, Pfizer’s non-COVID operational revenues are improving, driven by its ...

Roche has found redemption in a precision medicine approach following an earlier Tecentriq trial flop in a broader bladder ...

PD-1 inhibitors are projected to dominate future drug sales. Immuno-oncology therapies, particularly the PD-(L)1 class, have revolutionized cancer ca ...

The technology once embraced by President Donald Trump for speeding the development of COVID-19 vaccines is now under scrutiny. Health Secretary Robert F. Kennedy Jr. recently took sweeping action ...

Exelixis (EXEL) is developing zanzalintinib — a next-generation oral investigational tyrosine kinase inhibitor (TKI) — which ...